n.光辉（神）霉素

Mithramycin was discovered in 1952 by a team of scientists at the Searle Research Institute.
米特拉霉素是在1952年由赛勒研究所在一组科学家的发现中。
It gained prominence as an antibiotic for treating tuberculosis, particularly in resistant strains.
它因其在治疗肺结核，特别是对耐药菌株的有效性而备受关注。
Unfortunately, mithramycin has severe side effects, limiting its widespread use in clinical practice.
不幸的是，米特拉霉素有严重的副作用，这限制了其在临床实践中的广泛应用。
Researchers are currently exploring potential alternatives or modifications to minimize these adverse reactions.
研究人员正在探索可能的替代品或修改，以最小化这些不良反应。
Mithramycin therapy often requires close monitoring due to its toxicity, but it remains a valuable tool in specialized treatment regimens.
由于其毒性，米特拉霉素疗法通常需要密切监测，但它仍然是特殊治疗方案中的宝贵工具。
The drug's effectiveness against Mycobacterium tuberculosis prompted further investigation into its antibacterial properties.
该药物对抗结核分枝杆菌的有效性促使人们进一步研究其抗菌特性。
Mithramycin is not commonly prescribed anymore due to the development of more effective and safer antibiotics.
由于更有效和安全的抗生素的发展，米特拉霉素已不再常用。
Despite its drawbacks, mithramycin holds historical significance in the fight against tuberculosis.
尽管存在缺点，米特拉霉素在对抗肺结核的历史上具有重要意义。
Clinical trials are ongoing to evaluate if mithramycin can be repurposed for other infectious diseases.
正在进行临床试验，评估米特拉霉素是否能被重新用于治疗其他传染病。
Scientists continue to study mithramycin in hopes of finding new ways to overcome bacterial resistance.
科学家们仍在研究米特拉霉素，希望找到新的方法来克服细菌抗药性。